$19.92 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) Fails to deliver data

Key failure to deliver metrics for BeiGene :

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for BeiGene (BGNE) - 3 month history

Number of shares, 3 month chart

Biweekly Failures to deliver volume for BeiGene (BGNE) - since 2016

Volume in USD (price x number of shares), data since 2016

BeiGene (BGNE) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2023$36.83 M-62.71%
2022$98.76 M113.17%
2021$46.33 M-62.37%
2020$0.12 B40.02%
2019$87.92 M48.77%
2018$59.1 M255.99%
2017$16.6 M169.67%
2016$6.15 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
$1.25 M$7.12 M๐Ÿ‡บ๐Ÿ‡ธ USA
$0.05 M$0.27 M๐Ÿ‡บ๐Ÿ‡ธ USA